106 related articles for article (PubMed ID: 2503488)
1. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis.
Hjelte L; Malmborg AS; Strandvik B
J Antimicrob Chemother; 1989 Jun; 23(6):885-90. PubMed ID: 2503488
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin.
Schaad UB; Desgrandchamps D; Kraemer R
Acta Paediatr Scand; 1986 Jan; 75(1):128-38. PubMed ID: 3082103
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L
J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228
[TBL] [Abstract][Full Text] [Related]
4. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
Strandvik B; Malmborg AS; Alfredson H; Ericsson A
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study.
Huang NN; Palmer J; Keith H; Schidlow D; Braverman S; Goldberg M
J Antimicrob Chemother; 1983 May; 11 Suppl B():205-14. PubMed ID: 6352603
[TBL] [Abstract][Full Text] [Related]
7. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis.
Martini N; Agostini M; Barlocco G; Bozzini L; Castellani L; Messori A; Scroccaro G; Mastella G
J Clin Hosp Pharm; 1984 Dec; 9(4):303-9. PubMed ID: 6396321
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis.
McLaughlin FJ; Matthews WJ; Strieder DJ; Sullivan B; Goldmann DA
J Antimicrob Chemother; 1983 May; 11 Suppl B():195-203. PubMed ID: 6352602
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin.
Møller NE; Koch C; Vesterhauge S; Jensen K
Scand J Infect Dis; 1982; 14(3):207-11. PubMed ID: 6815787
[TBL] [Abstract][Full Text] [Related]
11. [Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
Grenier B; Gilly R
Presse Med; 1984 Mar; 13(13):815-8. PubMed ID: 6231602
[TBL] [Abstract][Full Text] [Related]
12. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
Conway SP; Miller MG; Ramsden C; Littlewood JM
Acta Paediatr Scand; 1985 Jan; 74(1):107-13. PubMed ID: 3885674
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Rubio TT; Shapiro C
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
[TBL] [Abstract][Full Text] [Related]
14. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
[TBL] [Abstract][Full Text] [Related]
15. Anti-pseudomonas activity of azlocillin during pulmonary infection in patients with cystic fibrosis.
Levy J; Baran D; Klastersky J
J Antimicrob Chemother; 1982 Sep; 10(3):235-8. PubMed ID: 6815156
[No Abstract] [Full Text] [Related]
16. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Bayer AS; Blomquist IK; Kim KS
J Antimicrob Chemother; 1986 May; 17(5):641-9. PubMed ID: 2941403
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients.
Bosso JA; Townsend PL; Herbst JJ; Matsen JM
Antimicrob Agents Chemother; 1985 Dec; 28(6):829-31. PubMed ID: 4083865
[TBL] [Abstract][Full Text] [Related]
18. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model.
Gerber AU; Kozak S; Segessenmann C; Flückiger U; Bangerter T; Greter U
Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):233-7. PubMed ID: 2496992
[TBL] [Abstract][Full Text] [Related]
19. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Malmborg AS; Alfredsson H; Kusoffsky E; Strandvik B
Scand J Infect Dis Suppl; 1981; 29():64-9. PubMed ID: 6947407
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of superinfections caused by pyocyanic bacillus in patients with mucoviscidosis. Efficacy of cefsulodin in combination with an aminoglycoside].
Jehanne M
Pathol Biol (Paris); 1989 May; 37(5):500-3. PubMed ID: 2780107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
